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http://dx.doi.org/10.1016/j.jinf.2013Summary Objectives: Toassess theburdenof influenzabyageandclinical status anduse this to
inform evaluations of the age and risk-based influenza vaccination policy in the United Kingdom.
Methods: Weekly laboratory reports for influenza and 7 other respiratory pathogens were ex-
tracted from the national database and used in a regression model to estimate the proportion
of acute respiratory illness outcomes attributable to each pathogen.
Results: Influenza accounted forw10% of the attributed respiratory admissions and deaths in hos-
pital. Healthy children under five had the highest influenza admission rate (1.9/1000). The presence
of co-morbidities increased theadmissionrateby5.7 fold for 5e14year olds (from0.1 to0.56/1000),
the relative risk declining to 1.8 fold in 65þ year olds (from0.46 to 0.84/1000). Themajority (72%) of
influenza-attributable deaths in hospital occurred in 65þ year olds with co-morbidities. Mortality in
children under 15 years was lowwith around 12 influenza-attributable deaths in hospital per year in
England; the case fatality ratewas substantially higher in risk than non-risk children. Infants under 6
months had the highest consultation and admission rates, around 70/1000 and 3/1000 respectively.
Conclusions: Additional strategies are needed to reduce the remaining morbidity and mortality in
the high-risk and elderly populations, and to protect healthy children currently not offered the ben-
efits of vaccination.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection Association.
Open access under CC BY license. u.au (D. Cromer).
hed by Elsevier Ltd on behalf of the The British Infection Association.
.11.013
Open access under CC BY license. 
364 D. Cromer et al.Introduction Materials and methodsInterest in prevention and control of seasonal influenza has
heightened in the wake of the recent influenza A(H1N1)v
pandemic. The World Health Organisation through its
Global Action Plan for Influenza Vaccines has spearheaded
a major initiative to increase influenza vaccine use and
production capacity,1 and additionally has recently revised
its global recommendations on vaccination policy.2 The
United Kingdom has a long-established influenza vaccina-
tion programme that targets all those aged 65 years and
over or in high-risk clinical groups. A major review of the
national programme was recently undertaken in the United
Kingdom that resulted in the recommendation for annual
influenza vaccination of all children aged 2e16 years.3
This recommendation was based on estimates of the burden
of disease by age under the existing programme in those
with and without high-risk clinical conditions, and model-
ling the likely impact of different vaccination strategies
on the transmission dynamics of seasonal influenza4 and
the cost effectiveness of these strategies.3
Estimating influenza disease burden is challenging as
symptoms are non-specific and few patients presenting with
an acute respiratory illness are routinely investigated for
virological evidence of influenza infection. Studies in which
all patients with acute respiratory illness are tested for
evidence of influenza are labour intensive and are usually
focused on a particular age range and conducted over a
limited number of seasons. This makes disease burden
comparisons between age groups difficult. Furthermore,
they may not capture differences between seasons in prev-
alent influenza strains, each of which may have its own
morbidity profile. Also, while risk factors in virologically
confirmedcasesmaybe ascertained, it is difficult to translate
these into relative risks in those with and without underlying
chronic conditions in the absence of comparable information
on the prevalence of such conditions in the population.
An alternative approach is to use regression models to
estimate the burden of influenza by comparing the seasonal
pattern of influenza and other respiratory pathogens with
seasonal variations in acute respiratory illness. Several
studies have used this method to assess influenza burden
but none has taken account of the effect of underlying
clinical risk on disease outcome. Furthermore, they have
been limited by failure to include non-viral respiratory
pathogens5e9 such a Streptococcus pneumoniae which has
been shown to be an important contributor to acute respi-
ratory illness.10 Existing analyses have also been criticised
for failing to incorporate relevant epidemiological features,
such as potential interactions between co-circulating respi-
ratory pathogens.11,12 We have developed a range of statis-
tical models that address these limitations. Our analysis
provide estimates of the number of influenza-associated
health care outcomes in different age groups in those
with and without high-risk conditions in England under
the existing influenza vaccination programme. Measuring
the effect of being in a high-risk group on the age-related
burden of influenza was essential for the modelling and
cost effectiveness analyses that underpinned the recent
decision in the United Kingdom to extend the existing age
and risk-based vaccination policy to healthy children.3Data sources
Data were obtained for the eight years immediately pre-
ceding the A(H1N1)v pandemic (2000/1 to 2007/8) and
arranged into epidemiological years April to March to
encompass the annual influenza season.
Laboratory reports: Public Health England receives
weekly computerised reports of clinically significant infec-
tions confirmed by microbiology laboratories in England
and Wales. The United Kingdom Standards for Microbiology
Investigations recommend the diagnostic algorithms that
should be applied to patients presenting with different clin-
ical syndromes in order to promote consistency in testing
over time and between laboratories.13 Weekly numbers of
reports by date of test and age group were obtained from
the national database for the following pathogens: influ-
enza A, influenza B, respiratory syncytial virus, parain-
fluenza, adenovirus, rhinovirus, S. pneumoniae,
Mycoplasma pneumoniae and Haemophilus influenzae.
Only invasive specimens of S. pneumoniae, M. pneumoniae
and H. influenzae were included due to lack of consistency
in reporting non-invasive isolates. The increasing use of
genomic detection methods for rhinovirus and parain-
fluenza resulted in a spurious temporal increase in these
respiratory viruses. Reports for these pathogens where
the method of detection was either “genomic detection”
or “antibody detection” were therefore omitted from the
analysis. The proportion of influenza A cases that are either
H1 or H3 subtypes was obtained from the results of routine
surveillance specimens taken by general practices in the
United Kingdom participating in the Royal College of Gen-
eral Practitioners Weekly Returns Service.14
Inpatient admissions: Weekly inpatient admissions to
National Health Service hospitals in England were obtained
from the Hospital Episode Statistics database.15 Patients
were included in the analysis if they had an acute respira-
tory illness code (ICD-10 codes J0*, J1*, J2*, J3*, J40*,
J41*, J42*, J43*, J44*, J47*) in any diagnosis field.
Identifying Clinical Risk Groups: Patients with an acute
respiratory illness code and with ICD-10 codes in other diag-
nostic fields for conditions indicated for seasonal influenza
vaccination were flagged as being in a clinical risk group;
see Supporting Text (Table S10) for a list of the ICD-10 co-
des which were used to identify patients in a risk group.
Deaths in hospital: The number of deaths in hospital by
age and clinical risk group was estimated by counting inpa-
tient admissions with an acute respiratory illness code ex-
tracted from the Hospital Episode Statistics database with
death recorded as the discharge method. Only deaths
within 30 days of admission were included in the analysis.
General practitioner consultations: The age-stratified
weekly numbers of consultations in general practice for
acute respiratory illness were obtained from the Royal Col-
lege of General Practitioners Weekly Returns Service. The
population monitored by the Royal College of General Prac-
titioners is closely matched to the national population in
terms of age, gender, deprivation index and prescribing
patterns.16 Consultation numbers were scaled by the size
of the population covered by the Royal College of General
Figure 1 Seasonal trends in numbers of laboratory reports in
England and Wales in two key age groups: 6 monthse4 years (A)
and 65 years and over (B). Data are presented as weekly results
averaged over eight epidemiological years (2000/1 to 2007/8).
Burden of influenza 365Practitioners practices (1.44% of population of England and
Wales) in 201016 to give weekly consultation rates per
100,000 people. These rates were then multiplied by the
population of England during the corresponding season to
give estimated weekly numbers of episodes. The data
were not available by clinical risk group.
Population by age and clinical risk group: The popula-
tion of England in clinical risk groups indicated for seasonal
influenza vaccination was estimated using the proportion of
patients identified in the Royal College of General Practi-
tioners practices as having a READ code indicating an influ-
enza high-risk condition, averaged between 2003 and 2010.
Statistical modelling
Weekly counts in the laboratory reports for pathogens
potentially responsible for acute respiratory illness were
used as explanatory variables to estimate the proportion of
health care outcomes (acute respiratory illness episodes
leading to GP consultations, hospital admissions and deaths
in hospital) attributable to influenza. We used an adapta-
tion of a generalised linear model for negative binomial
outcome distributions with an identity link function. The
negative binomial distribution was used to account for
overdispersion in many of the outcome variables and the
identity link function to ensure contributions from different
pathogens were additive (see Supporting Text Section 1 for
model equations). The models were constructed by allow-
ing for the incorporation of i) a moving average to smooth
fluctuations in laboratory reports; ii) a secular trend in out-
comes iii) the separation of influenza A into its subtypes; iv)
the effects of interactions between co-circulating patho-
gens and v) a temporal offset between pathogen testing
and the onset of clinical effect. Details are provided in Sec-
tions 1 and 2 of the Supporting Text. The best fitting model
was selected using the Akaike Information Criterion. We
observed that all model variations with an Akaike Informa-
tion Criterion value close to that of the selected model pro-
duced a similar estimate for the proportion of influenza-
attributable hospitalisations, indicating that the exact
choice of model construction did not dramatically influence
our estimates (see Supporting Text, Section 2). Model out-
comes were stratified by age (<6 months, 6 months to 4
years, 5e14 years, 15e44 years, 45e64 years and 65þ)
and clinical risk group. Due to the small number of deaths
in hospital in patients under 65 years patients were grouped
into <15 years and 15e64 years to estimate influenza-
attributable deaths in hospital.
Results
Laboratory reports and acute respiratory illness
admissions
Seasonal variations in the numbers of laboratory reports for
the 8 pathogens likely to cause acute respiratory illness are
shown in Fig. 1 for two key age groups: 6 monthse4 years
(panel A) and 65 years and over (panel B). Respiratory syn-
cytial virus dominates reports in young children during
winter, while S. pneumoniae dominates reports in older
people throughout the year, but especially during winter.For influenza, there is substantial variation between sea-
sons in the number of laboratory-confirmed cases by age
group and strain (Fig. 2)
There was an annual average of over 300,000 admissions
for acute respiratory illness among those without co-
morbidities and almost 520,000 among those in a clinical
risk group; themajorityof theadmissions and thehighest case
fatality rateswere in65þ yearolds (Table1). Inall agegroups,
the incidence per 1000 population of admission for acute res-
piratory illness was higher in those with a clinical risk. For
those under 65 years of age, the risk of dying in hospital was
much higher for those in a clinical risk group, declining from
35.1 times higher in <6 month olds to 5.9 times higher in
45e64 year olds. In 65þ year olds the case fatality rate was
similar in those with and without a clinical risk.
Model fitting and attribution of health outcomes to
different pathogens
The best fitting model to the weekly number of episodes
leading to hospital admissions, consultations in general
Figure 2 Number of influenza A and B reports in England and
Wales by season and age group 2000/1 to 2007/8.
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averages to within 1% (Supporting Text e Section 4). This
model was one that incorporated a moving average to
smooth out laboratory reports, and a linear increase in
the number of hospitalisations not attributable to specific
respiratory pathogens. Separation of influenza A into sub-
types, allowing for interactions between co-circulating
pathogens and incorporating a temporal offset did not
improve model fit. Detailed results of the fitting process,
and examples comparing the best fitting model results
with data on the weekly number of hospital admissions,
GP consultations and deaths for various age and risk groups
are presented in the Supporting Text (Sections 1e3). The
contributions of the various pathogens to the attributeddisease burden are shown in the Supporting Text e
Section 4. In both risk and non-risk groups, S. pneumoniae
and respiratory syncytial virus consistently account for
the largest numbers of hospital admissions and deaths
across all ages groups with influenza is usually the third
most common pathogen accounting for an overall 9% and
11% respectively of the attributed acute respiratory illness
admissions and deaths in hospital (and 2% and 3% respec-
tively of the total number of acute respiratory illness ad-
missions and deaths in hospital). There were some
differences between risk and non-risk groups in the propor-
tion of disease burden attributed to specific pathogens; for
example H. influenzae is an important pathogen among risk
group patients aged 65þ years of age but not in the non-risk
elderly. Parainfluenza was responsible for 7% of deaths in
hospital among risk groups but was not identified as a cause
of mortality among non-risk groups.Influenza-attributable burden of disease
Table 2 shows the average annual influenza-attributable hos-
pital admission rateper 100,000by strain, ageand risk status.
The highest admission rates for both influenza A and B are in
children under five years of age, for whom the overall admis-
sion rate is 1.9/1000 (95%CI 0.023/1000); with no evidence
of a higher overall rate in those with clinical risk factors.
Overall, children under 15 years of age accounted for 37%
of all annual influenza-attributable hospital admissions and
52% of admissions among those in non-risk groups (Fig. 3).
Among older age groups the effect of being in a risk group
increased the hospital admission rate between 5.7 fold for
5e14 year olds (from 0.1 to 0.56/1000) and 1.8 fold for 65þ
year olds (from 0.46 to 0.84/1000). Among those aged 15
years and over there was little contribution from influenza
B to admissions.
The estimated annual number of deaths in hospital from
influenza for the three age groups <15, 15e64 and 65þ year
olds are shown in Table 3 by risk status. Few deaths in hos-
pital were estimated in children under 15 years of age, the
annual average of 12 in England giving an estimated mortal-
ity rate of 1.3 per million overall for this age group. The
vast majority of the annual deaths occurred in the 65þ
age group (1676 of 1806, 93%), particularly those with un-
derlying co-morbidities (1298, 72% of the total). The case
fatality rate in risk group patients was between 38.6 and
2.3 fold higher than among non-risk group patients, the
relative risk decreasing with age.
Children under 15 years of age have the highest rate of
influenza-attributable episodes leading to consultations in
general practice and bear the largest burden of disease due
to influenza B (Table 4). Of the estimated 1,084,283 annual
total consultations for influenza, 420,831 (39%) were in this
age group (Supporting Table S5). For both consultations and
admissions, the rates in infants under 6 months of age are
particularly high, around 70 per 1000 and 3 per 1000 respec-
tively. Unlike hospitalisations, the consultation rate for
influenza does not increase in the elderly. In consequence,
the ratio between consultation and admission rates varies
with age and influenza strain and was lowest for the 65þ
age group (9.2) and highest for 5e14 year olds (270) for
both strains combined.
Table 1 Average annual admissions and death and the case fatality rate (CFR) in hospital for acute respiratory illness (ARI) by
age and clinical risk group for the epidemiological years 2000/1 to 2007/8.
Age Not at clinical risk Clinical risk CFR ratio
Clinical risk/not
clinical risk (95% CI)
Admissions Incidence
per 1000
Deaths Case fatality
rate (Deaths/
1000 admissions)
Admissions Incidence
per 1000
Deaths Case fatality
rate (Deaths/
1000 admissions)
<6 m 24,743 84.5 11 0.4 1408 161.1 22 15 35.1 (26.8e46.2)
6 me4 y 83,977 33.6 17 0.2 12,008 84.8 55 5 22.6 (18.4e27.8)
5e14 y 42,649 7.7 10 0.2 9874 16.3 51 5 22.0 (17.1e28.5)
15e44 y 87,985 4.6 112 1.3 29,337 15.4 674 23 18.0 (16.7e19.5)
45e64 y 39,353 3.9 364 9.3 99,337 44.1 5458 56 5.9 (5.7e6.2)
65þ y 53,254 12.1 7729 144.8 368,489 101.6 54,933 151 1.03 (1.02e1.04)
All ages 331,960 7.9 8244 24.9 520,453 61.0 61,192 119 4.73 (4.69e4.77)
Burden of influenza 367The annual variations in influenza-attributable hospital
admissions, deaths in hospital and GP consultation rates by
age and risk group status are shown in the Supporting Text,
Section 5.Discussion
Principal findings
We used microbiological and epidemiological surveillance
data for England and Wales to estimate health outcomes
attributable to influenza and other respiratory pathogens
under the existing age- and risk-based national influenza
vaccination programme. Our study shows that despite
targeting vaccination at these vulnerable groups their
disease burden is still disproportionately high compared
with individuals in the same age group without co-
morbidities, particularly in those under 65 years of age.
Among 65þ year olds, the effect of underlying co-
morbidities on hospitalisation and case fatality rates was
less marked. Overall this age group contributed 93% all
influenza-attributable deaths in hospital though only 29% of
all admissions due to influenza (Table 3). Healthy children
under 5 years of age had the highest influenza-
attributable hospital admission rates, over 5 fold higher
than 65þ year olds. Nearly 40% of the hospital admissionsTable 2 Mean estimated annual incidence (95% Confidence Inte
age and clinical risk group (epidemiological years 2000/1 to 2007
Hospitalisations annual rate per 100,000 (95% CI)
Age Not at clinical risk Clinical ri
Flu A Flu B All Flu Flu A
<6 m 198 (10) 135 (8) 333 (12) 0 (0)
6 me4 y 149 (4) 27 (3) 176 (5) 153 (11)
5 ye14 y 10 (0.8) 0 (0) 10 (0.8) 36 (2)
15e44 y 9 (0.3) 0 (0) 9 (0.3) 42 (1)
45e64 y 11 (0.3) 6 (0.2) 16 (0.3) 74 (3)
65þ y 46 (1) 0 (0) 46 (1) 84 (7)
All Ages 23 (0.3) 4 (0.2) 27 (0.4) 70 (3)and consultations for influenza were in children under 15
years of age though annual mortality in this age group
was low at around 1.3/million population.
Our study provides evidence to support the approach
adopted in many developed countries of targeting influenza
vaccination at high-risk individuals and the elderly. How-
ever, it also shows the limitation of such selective
approaches in mitigating the consequences of disease in
these vulnerable groups and suggests the need for addi-
tional prevention strategies. Vaccine coverage in England
among those aged 65 years and over has been around 75%
since 2005/6,17 meeting the target uptake recommended
by the European Union Council for this age group.18 Howev-
er, the relatively low vaccine efficacy in those aged 65
years and over19 limits its impact on morbidity and mortal-
ity in this age group. Vaccine coverage in high-risk individ-
uals under 65 years of age, such as those with cardiac,
pulmonary or metabolic disorders, is low and has remained
at around 50% since 2008/9 in England20 despite the recent
experience with AH1N1 (2009) pandemic influenza which
demonstrated the substantially higher morbidity and mor-
tality in these groups.21,22 While vaccine uptake in these
high-risk individuals needs to be improved, it is unlikely
that this would be sufficient to abolish their morbidity
and mortality differential given that vaccine efficacy
against confirmed infection is only around 70% in a matched
year in healthy adults23 and, if hospitalised with influenza,rval) of influenza attributable hospital admissions by strain,
/8) and relative risk of hospitalisation if in a risk group.
sk Relative risk of hospitalisation
if in a risk group
Flu B All Flu All flu
227 (21) 227 (21) 0.7 (0.6e0.8)
0 (0) 153 (11) 0.9 (0.8e0.9)
20 (2) 56 (3) 5.7 (5.2e6.3)
0 (0) 42 (1) 4.9 (4.7e5.1)
0 (0) 74 (3) 4.5 (4.3e4.7)
0 (0) 84 (7) 1.8 (1.7e2)
2 (0.1) 71 (3) 2.7 (2.5e2.8)
Figure 3 Percentage of total annual hospital admissions for
influenza by age group and risk status.
368 D. Cromer et al.high-risk individuals have substantially higher case fatality
rates (Table 3).
The highest annual influenza-attributable admission and
consultation rates were in infants under 6 months of age
who, although too young to be vaccinated themselves,
could benefit from maternal immunisation in pregnancy
which has been shown to be 63% effective in reducing
laboratory confirmed influenza in infants in the first 6
months of life.24 The importance of offering influenza
vaccination in pregnancy was recently emphasised by the
World Health Organisation who identified pregnant womenTable 3 Estimated annual number of influenza admissions and
fidence interval by age group and risk status, and relative risk of
Age
group
Not at clinical risk Clin
Estimated
number of
influenza
admissions
(95% CI)
Estimated
number of
influenza
deaths in
hospital
(95% CI)
Deaths/1000
influenza
admissions
(95% CI)
Est
infl
adm
(9
0e14 y 5862 (137) 2.5 (0.3) 0.43 (0.38e0.49) 57
15e64 y 3297 (61) 20 (1.2) 6.1 (5.7e6.4) 245
65þ 2040 (46) 378 (11) 185 (179e192) 302
All Ages 11,199 (157) 400 (11) 36 (35e37) 605
Table 4 Influenza-attributable GP consultations and hospitalisa
to admissions (95% confidence intervals).
Age GP consultations annual
rate per 100,000 (95% CI)
Hosp
rate
(95
Flu A Flu B All Flu Flu A
<6 m 4829 (233) 2532 (195) 7361 (304) 192
6 me4 y 3916 (137) 2174 (101) 6090 (170) 149
5 ye14 y 2131 (62) 1744 (88) 3875 (107) 12
15e44 y 1327 (25) 552 (24) 1878 (35) 12
45e64 y 1468 (26) 361 (21) 1829 (34) 22
65þ y 582 (26) 0 (0) 582 (26) 63
All Ages 1496 (17) 660 (16) 2156 (23) 31as the highest priority group for vaccination.2 However
coverage in pregnant women in England is poor only reach-
ing 25.5% in those without co-morbidities in 2011/12.20
There were marked differences between age groups in
the ratio of consultation rates in general practice to hospi-
tal admission rates for influenza (Table 4). Consultation
rates will not only reflect the underlying infection rate in
that age group but also the propensity to consult for an
influenza-like-illness if symptomatically infected. Similarly,
hospital admission rates will reflect the age-specific
severity profile as well as the age-specific incidence of
infection. Quantifying the relationship between health
care outcomes and the underlying infection rate in each
age group is essential for building influenza transmission
models that can assess the overall population impact of
different vaccination polices. Estimation of age-specific
influenza infection rates requires data from serological
studies conducted before and after the influenza season.
The value of seroepidemiology was recognised as a result
of the H1N1 (2009) pandemic25 but has not been systemat-
ically applied to seasonal influenza.
Strengths and weaknesses of our study
The strength of our study is that it enables a comparison of
the influenza-attributable morbidity between age groups
and the effect of underlying co-morbidities within an agedeaths in hospital and case fatality rate (CFR) with 95% con-
dying in hospital if in a clinical risk group for influenza.
ical risk CFR ratio
Clinical risk/
not clinical
risk (95% CI)
imated #
uenza
issions
5% CI)
Estimated
number of
influenza
deaths in
hospital
(95% CI)
Deaths/1000
influenza
admissions
(95% CI)
3 (22) 10 (0.6) 17 (15e18) 38.6 (33.4e44.8)
2 (70) 98 (7) 40 (37e43) 6.6 (6.0e7.3)
9 (255) 1298 (56) 428 (391e473) 2.3 (2.1e2.6)
4 (266) 1406 (56) 232 (219e246) 6.5 (6.1e6.9)
tion rates by age, entire population and ratio of consultations
italisations annual
per 100,000
% CI)
Ratio GP consultations:
hospital admissions
(95% CI)
Flu B All Flu All Flu
(9) 138 (8) 330 (12) 22.3 (22.1e23.6)
(4) 26 (3) 175 (5) 34.9 (33.5e36.3)
(0.8) 2 (0.2) 14 (0.8) 270 (254e288)
(0.3) 0 (0) 12 (0.3) 160 (155e164)
(0.6) 5 (0.2) 27 (0.6) 68.1 (66.1e70.0)
(3) 0 (0) 63 (3) 9.2 (8.6e9.8)
(0.6) 4 (0.2) 34 (0.6) 62.9 (61.6e64.2)
Burden of influenza 369group. Also, by using data from eight consecutive years, our
estimates will reflect the variation in influenza incidence
and severity between seasons. Our regression method uses
the year-to-year changes in the timing of the influenza
season as well as in the other respiratory pathogens that
are more prevalent in winter. Thus it also allows the burden
of disease attributable to influenza to be compared with
other respiratory pathogens such as respiratory syncytial
virus and S. pneumoniae. It shows that together these
latter two pathogens are responsible for around 60% all
attributed hospital admitted acute respiratory illness in
both risk and non-risk individuals. Our analysis also identi-
fied H. influenzae and parainfluenza as important patho-
gens in individuals with underlying co-morbidities.
A potential limitation of this work is that we restricted
our mortality analyses to patients with acute respiratory
illness who die in hospital to allow derivation of case
fatality rates for those in high-risk groups compared with
non-risk individuals. This was essential for the cost-
effectiveness analysis that was undertaken to evaluate
the effect of different extensions to the current risk-
based influenza vaccination programme3 and will ensure
that the results are conservative. For example, the annual
number of influenza-attributable deaths in those aged 75
years and over obtained by regression methods using all-
cause mortality as the outcome was around 10,0006
compared with our estimate of under 1700 influenza-
attributable deaths in hospital in those aged 65 years
and over, Another limitation is that we also restricted
our analysis to hospitalisations for acute respiratory
illness and did not consider the association between influ-
enza and cardiovascular-related morbidity (specifically
myocardial infarction and stroke26). However, a recent
study in England and Wales only found a significant associ-
ation between influenza and myocardial infarction in pa-
tients 80 years old and over.27 Furthermore, only 0.7%e
1.2% of myocardial infarction-associated hospitalisations
were estimated to be influenza-attributable. This would
amount to around 1000 additional hospitalisations a
year, compared to the 17,000 (all ages) we estimated in
our model to be associated with influenza. Since, the
increased risk of myocardial infarction and stroke lasts
up to three months following the influenza episode,26 it
is unclear how such potentially long time lags can be
robustly incorporated in these types of time-series
models. Where possible we used data sources covering
the entire United Kingdom, however in some cases data
was only available for either England (hospital admissions
and deaths) or England and Wales (laboratory reports).
Due to the restriction on available hospitalisation data,
where absolute numbers are presented, they relate to ab-
solute numbers in England only.
The strength of our regression method is that we
incorporated adjustments suggested by others11,12 by
fitting 9 different models. We observed that some of these
adjustments, namely allowing for interactions between co-
circulating pathogens and incorporating a temporal offset
did not improve model fit and are therefore perhaps less
important in practice. The regression method relies on
the assumption that the temporal variation in reports of
the different causative pathogens accurately reflects their
relative incidence over time in the study populations. It ispossible that there may be some seasonal variation in pat-
terns of laboratory testing, but the recommended Stan-
dards for Microbiology Investigations [12] should minimise
this. Interestingly, we found an increasing trend in hospital-
isations that was not matched by increases in laboratory re-
ports. This necessitated the incorporation of a trend term
in the regression model in order to focus on the seasonal
fluctuations in acute respiratory illness. A similar increase
in pneumonia hospitalisations has been previously noted
and remains unexplained.28
It is reassuring that where our estimates could be
compared with those from virological studies, the results
were similar. For example our estimated annual influenza-
related hospitalisation was 1.9 per 1000 children under 5
years, similar to an estimate for severe influenza-
attributable acute lower respiratory infection of 1 per
1000 children under 5 years (95% CI 1e2) in a meta-
analysis of virological studies in developed countries.29 It
is also similar to estimates of the incidence of influenza-
related hospitalisations in two English studies in which chil-
dren admitted with a respiratory illness were virologically
investigated: 1.44 per 1000 (95% CI 1.17e1.75) in children
under 6 years in Leicester in 2001e2002,30 and 1.57 per
1000 in children under 5 years in East London in
2002e2004.31 Like us, the authors of the meta-analysis
found that the highest rate of severe influenza in children
in developed countries was in infants under 6 months of
age, 340 per 100,00 (95% CI 230e500) (personal communica-
tion Dr. H. Nair) which is very similar to our estimate of 330
(95% CI 318e342).
Policy implications and future research
Our analyses indicate that additional strategies are needed
to reduce the remaining morbidity and mortality in the
high-risk and elderly populations, and to protect healthy
children who are currently not offered the benefits of
vaccination. Children play a key role in transmission of
influenza and their vaccination is likely to bring additional
herd immunity benefits.4 Vaccine coverage among pregnant
women needs to improve both for their own protection and
that of their infants during the first 6 months of life when
influenza morbidity is highest. Annual age-stratified sero-
logical studies are needed to help understand the transmis-
sion dynamics of seasonal influenza and to document the
impact on transmission of the annual vaccination of chil-
dren aged 2e16 years which is now recommended in the
United Kingdom to complement the age and risk-based pol-
icy in place since 2000.3 The same features in influenza
burden may be present in other developed countries with
a similar age and risk-based influenza vaccination pro-
gramme; hence there may be value in considering similar
policies in such settings.
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